Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies
| Autor: | Jeanne Tie, Andrea Muranyi, Michael Christie, Paul Michael Waring, Peter Gibbs, Rebecca Bowermaster, Sabine Lohmann, Pia Herrmann, Susen Burock, Katharina Ilm, Janice Smith, Astrid Reiser, Ulrike Stein, Patrick Brunhoeber, Hai Zhang, Marc Osterland, Shalini Singh, Hui-Li Wong, Ulrich-Peter Rohr, Katherine Leith, Kandavel Shanmugam |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Colorectal cancer DNA Mismatch Repair Disease-Free Survival Metastasis Cohort Studies 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Adjuvant therapy Humans Neoplasm Staging Gynecology business.industry Microsatellite instability Hematology medicine.disease Prognosis Chemotherapy regimen Confidence interval 030104 developmental biology 030220 oncology & carcinogenesis Cohort Colonic Neoplasms Trans-Activators Neoplasm Recurrence Local business Cohort study Transcription Factors |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 28(8) |
| ISSN: | 1569-8041 |
| Popis: | Background We assessed the novel MACC1 gene to further stratify stage II colon cancer patients with proficient mismatch repair (pMMR). Patients and methods Four cohorts with 596 patients were analyzed: Charite 1 discovery cohort was assayed for MACC1 mRNA expression and MMR in cryo-preserved tumors. Charite 2 comparison cohort was used to translate MACC1 qRT-PCR analyses to FFPE samples. In the BIOGRID 1 training cohort MACC1 mRNA levels were related to MACC1 protein levels from immunohistochemistry in FFPE sections; also analyzed for MMR. Chemotherapy-naive pMMR patients were stratified by MACC1 mRNA and protein expression to establish risk groups based on recurrence-free survival (RFS). Risk stratification from BIOGRID 1 was confirmed in the BIOGRID 2 validation cohort. Pooled BIOGRID datasets produced a best effect-size estimate. Results In BIOGRID 1, using qRT-PCR and immunohistochemistry for MACC1 detection, pMMR/MACC1-low patients had a lower recurrence probability versus pMMR/MACC1-high patients (5-year RFS of 92% and 67% versus 100% and 68%, respectively). In BIOGRID 2, longer RFS was confirmed for pMMR/MACC1-low versus pMMR/MACC1-high patients (5-year RFS of 100% versus 90%, respectively). In the pooled dataset, 6.5% of patients were pMMR/MACC1-low with no disease recurrence, resulting in a 17% higher 5-year RFS [95% confidence interval (CI) (12.6%–21.3%)] versus pMMR/MACC1-high patients (P = 0.037). Outcomes were similar for pMMR/MACC1-low and deficient MMR (dMMR) patients (5-year RFS of 100% and 96%, respectively). Conclusions MACC1 expression stratifies colon cancer patients with unfavorable pMMR status. Stage II colon cancer patients with pMMR/MACC1-low tumors have a similar favorable prognosis to those with dMMR with potential implications for the role of adjuvant therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|